Replay of the Aprea Therapeutics Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor  Watch here

Contact Aprea

Learn more about our DDR-targeted therapeutics, clinical trials, and more.

Please fill out and submit our contact form or write to us directly at [email protected]

3805 Old Easton Rd., Doylestown, PA 18902

Contact Us